Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
6.13
0.00 (0.00%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 9.17, with a low estimate of 8.50 and a high estimate of 10. The average target predicts an increase of 49.59% from the current stock price of 6.13.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CTKB stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $8.5 | Buy | Maintains | $8 → $8.5 | +38.66% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +30.51% | Aug 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8.5 | Buy | Maintains | $10 → $8.5 | +38.66% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +63.13% | Mar 6, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +63.13% | Feb 29, 2024 |
Financial Forecast
Revenue This Year
208.17M
from 193.02M
Increased by 7.85%
Revenue Next Year
239.03M
from 208.17M
Increased by 14.82%
EPS This Year
-0.08
from -0.09
EPS Next Year
0.07
from -0.08
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 216.8M | 258.8M | 294.3M |
| Avg | 208.2M | 239.0M | 268.3M |
| Low | 198.7M | 213.2M | 232.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 12.3% | 24.3% | 23.1% |
| Avg | 7.9% | 14.8% | 12.2% |
| Low | 2.9% | 2.4% | -2.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.05 | 0.16 | 0.17 |
| Avg | -0.08 | 0.07 | 0.11 |
| Low | -0.14 | -0.03 | 0.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 128.8% |
| Avg | - | - | 45.8% |
| Low | - | - | -19.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.